Randomized, Single-dose, Open-label, Two-part, Two-period, Cross-over Study to Compare the Pharmacokinetics, Safety and Tolerability of the Pediatric With an Adult Formulation of Branaplam and to Investigate the Adult Formulation in Fed and Fasted State in Healthy Participants
Overview
- Phase
- Phase 1
- Intervention
- LMI070
- Conditions
- Healthy Volunteers
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 9
- Locations
- 1
- Primary Endpoint
- Part 1: Plasma Cmax
- Status
- Terminated
- Last Updated
- 2 years ago
Overview
Brief Summary
This is a Phase 1 study designed to assess the relative bioavailability (BA), safety and tolerability and PK of the pediatric and adult formulations of branaplam.
Detailed Description
This study is to compare the pharmacokinetics, safety and tolerability of the pediatric and adult branaplam formulation in healthy adults. The study will also clarify if dosing with food can affect the PK of the adult formulation in order to guide recommendations on dosing relative to meals in subsequent studies. It is two-part, two-period, cross-over study in healthy participants which means that participants will receive both doses and take the treatment with and without food. The total study duration for each participant is expected to be up to approximately 88 days, including the Screening period and safety FU call. Participants will be required to be stay at the site overnight for 6 days during each period to receive dose and have multiple blood draws.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy male and non-childbearing potential female participants, 18 to 60 years of age inclusive, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening and baseline 1 (laboratory parameters are listed in Table 8-
- •Participants must weigh at least 50 kg at screening to participate in the study, and must have a body mass index within the range of 18.0 to 30.0 kg/m2 as measured at screening. Body mass index = Body weight (kg) / \[Height (m)\]
- •At screening and baseline vital signs (systolic blood pressure, diastolic blood pressure and pulse rate) will be assessed in the supine position and again in the standing position (after at least 3 minutes in each position). Oral body temperature will also be taken with the other supine vital sign assessments. Supine vital signs must be within the following ranges at screening and baseline 1:
- •oral body temperature 35.0-37.5 °C (inclusive)
- •systolic blood pressure, 90-139 mmHg (inclusive)
- •diastolic blood pressure, 50-89 mmHg (inclusive)
- •pulse rate, 40-90 bpm (inclusive) Participants should be excluded if their standing vital signs (relative to supine) show findings which, in the opinion of the Investigator, are associated with clinical manifestation of postural hypotension (i.e. absence of any other cause). An Investigator should carefully consider enrolling participants with either a \> 20 mmHg decrease in systolic blood pressure or a \> 10 mmHg decrease in diastolic blood pressure accompanied by a \> 20 bpm increase in pulse rate.
Exclusion Criteria
- •Participants who have received any investigational medicinal product in a clinical research study within the 90 days or 5 half-lives, whichever is longer, prior to Period 1 Day
- •Participants who have previously been administered investigational medicinal product in this study. Participants who have taken part in Part 1 are not permitted to take part in Part
- •Significant illness, which has not resolved within two (2) weeks prior to initial dosing.
- •Men planning to father children in the near future (next 6 months).
- •Male participant who reports to have a pregnant or nursing (lactating) partner.
- •Sexually active males unwilling to adhere to the contraception requirements of the study as detailed below:
- •A condom is required for all sexually active male participants to prevent them from fathering a child AND to prevent delivery of the investigational drug via seminal fluid to their partner.
- •Males with partners of childbearing potential must use a condom during intercourse while taking investigational drug and for 118 days after stopping investigational drug (duration to cover one spermatogenesis cycle plus 5 half-lives).
- •Additionally, male participants with female partners of childbearing potential should also use another highly effective method of contraception. Highly effective contraception methods include:
- •Partner's bilateral tubal occlusion Male participant sterilization (vasectomy; at least 6 months prior to screening).
Arms & Interventions
Pediatric Formulation
Part 1 - healthy participants receiving pediatric formulation
Intervention: LMI070
Adult Formulation
Part 1 - healthy participants receiving adult formulation
Intervention: LMI070
Adult formulation fasted state
Part 2- healthy participants receiving adult formulation in fasted conditions
Intervention: LMI070
Adult formulation Fed state
Part 2- Part 2- healthy participants receiving adult formulation in fed conditions
Intervention: LMI070
Outcomes
Primary Outcomes
Part 1: Plasma Cmax
Time Frame: Day 1, 2, 3, 4, 5, 8, 11 and 15
Assess relative bioavailability of adult vs pediatric formulation of branaplam under fasting conditions
Part 1: Plasma AUClast
Time Frame: Day 1, 2, 3, 4, 5, 8, 11 and 15 in each period
Assess relative bioavailability of adult vs pediatric formulation of branaplam under fasting conditions
Part 1: Plasma AUCinf
Time Frame: Day 1, 2, 3, 4, 5, 8, 11 and 15 in each period
Assess relative bioavailability of adult vs pediatric formulation of branaplam under fasting conditions
Part 2:Plasma Cmax
Time Frame: Day 1, 2, 3, 4, 5, 8, 11 and 15 in each period
Investigate food effect on the pharmacokinetics of the adult formulation of branaplam
Part 2: Plasma AUClast
Time Frame: Day1, 2, 3, 4, 5, 8, 11 and 15 in each period
Investigate food effect on the pharmacokinetics of the adult formulation of branaplam
Part 2: Plasma AUCinf
Time Frame: Day 1, 2, 3, 4, 5, 8, 11 and 15 in each period
Investigate food effect on the pharmacokinetics of the adult formulation of branaplam
Secondary Outcomes
- Parts 1 & 2: Plasma AUClast(Day 1, 2, 3, 4, 5, 8, 11 and 15 in each period)
- Parts 1 & 2: Plasma Tmax(Day 1, 2, 3, 4, 5, 8, 11 and 15 in each period)
- Parts 1 & 2: T1/2(Day 1, 2, 3, 4, 5, 8, 11 and 15 in each period)
- Parts 1 & 2: Plasma Cmax(Day 1, 2, 3, 4, 5, 8, 11 and 15 in each period)
- Parts 1 & 2: Plasma Vz/F(Day 1, 2, 3, 4, 5, 8, 11 and 15 in each period)
- Parts 1 &2: Plasma AUCinf(Day 1, 2, 3, 4, 5, 8, 11 and 15 in each period)
- Parts 1 & 2: Plasma CL/F(Day 1, 2, 3, 4, 5, 8, 11 and 15 in each period)
- Number of Adverse events and Serious adverse events(Day 1 up to 30 days after last drug administration)